S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
Delta Airline’s Put Option Activity Isn’t Bad News
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
Foot Locker Builds Up Another Head of Steam; Gains Imminent
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
Delta Airline’s Put Option Activity Isn’t Bad News
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
Foot Locker Builds Up Another Head of Steam; Gains Imminent
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
Delta Airline’s Put Option Activity Isn’t Bad News
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
Foot Locker Builds Up Another Head of Steam; Gains Imminent
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
Delta Airline’s Put Option Activity Isn’t Bad News
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
Foot Locker Builds Up Another Head of Steam; Gains Imminent
NASDAQ:TVTX

Travere Therapeutics (TVTX) Stock Price, News & Analysis

$7.71
+0.04 (+0.52%)
(As of 03/28/2024 ET)
Today's Range
$7.41
$7.97
50-Day Range
$7.18
$9.32
52-Week Range
$5.25
$23.17
Volume
776,017 shs
Average Volume
1.14 million shs
Market Capitalization
$586.73 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$17.85

Travere Therapeutics MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.60 Rating Score
Upside/​Downside
131.5% Upside
$17.85 Price Target
Short Interest
Bearish
13.23% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.68mentions of Travere Therapeutics in the last 14 days
Based on 5 Articles This Week
Insider Trading
Selling Shares
$439,024 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($3.10) to ($1.85) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.64 out of 5 stars

Medical Sector

494th out of 938 stocks

Pharmaceutical Preparations Industry

233rd out of 430 stocks

TVTX stock logo

About Travere Therapeutics Stock (NASDAQ:TVTX)

Travere Therapeutics, Inc., a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases. Its products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones. The company's clinical-stage programs consist of Sparsentan, a novel investigational product candidate, which has been granted Orphan Drug Designation for the treatment of focal segmental glomerulosclerosis in the U.S. and Europe; and Pegtibatinase (TVT-058), a novel investigational human enzyme replacement candidate being evaluated for the treatment of classical homocystinuria. It has a cooperative research and development agreement with National Institutes of Health's National Center for Advancing Translational Sciences and Alagille Syndrome Alliance for the identification of potential small molecule therapeutics for Alagille syndrome. The company was formerly known as Retrophin, Inc. and changed its name to Travere Therapeutics, Inc. in November 2020. Travere Therapeutics, Inc. was incorporated in 2008 and is headquartered in San Diego, California.

TVTX Stock Price History

TVTX Stock News Headlines

Central Banks Preparing for US Dollar Collapse?
China is spearheading this blatant de-dollarization push, dominating the physical gold market through massive central bank buying. Their ultimate goal? Ditching the greenback in favor of local BRICS currencies.
Central Banks Preparing for US Dollar Collapse?
China is spearheading this blatant de-dollarization push, dominating the physical gold market through massive central bank buying. Their ultimate goal? Ditching the greenback in favor of local BRICS currencies.
TVTX Mar 2024 30.000 call
Travere Therapeutics: Restructuring Away From Disaster
See More Headlines
Receive TVTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Travere Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/15/2024
Today
3/29/2024
Next Earnings (Estimated)
5/02/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:TVTX
Employees
380
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$17.85
High Stock Price Target
$35.00
Low Stock Price Target
$9.00
Potential Upside/Downside
+131.5%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.60
Research Coverage
15 Analysts

Profitability

Net Income
$-111,400,000.00
Pretax Margin
-258.96%

Debt

Sales & Book Value

Annual Sales
$145.24 million
Book Value
$2.67 per share

Miscellaneous

Free Float
73,244,000
Market Cap
$586.73 million
Optionable
Optionable
Beta
0.58
Investing Strategies To Help Grow Your Retirement Income Cover

Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.

Get This Free Report

TVTX Stock Analysis - Frequently Asked Questions

Should I buy or sell Travere Therapeutics stock right now?

15 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Travere Therapeutics in the last year. There are currently 6 hold ratings and 9 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" TVTX shares.
View TVTX analyst ratings
or view top-rated stocks.

What is Travere Therapeutics' stock price target for 2024?

15 Wall Street analysts have issued twelve-month price objectives for Travere Therapeutics' stock. Their TVTX share price targets range from $9.00 to $35.00. On average, they predict the company's share price to reach $17.85 in the next twelve months. This suggests a possible upside of 131.5% from the stock's current price.
View analysts price targets for TVTX
or view top-rated stocks among Wall Street analysts.

How have TVTX shares performed in 2024?

Travere Therapeutics' stock was trading at $8.99 on January 1st, 2024. Since then, TVTX stock has decreased by 14.2% and is now trading at $7.71.
View the best growth stocks for 2024 here
.

When is Travere Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 2nd 2024.
View our TVTX earnings forecast
.

How were Travere Therapeutics' earnings last quarter?

Travere Therapeutics, Inc. (NASDAQ:TVTX) announced its quarterly earnings data on Thursday, February, 15th. The company reported ($1.16) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.27) by $0.11. The business earned $45.06 million during the quarter, compared to the consensus estimate of $41.25 million. Travere Therapeutics had a negative trailing twelve-month return on equity of 177.97% and a negative net margin of 56.02%.

What ETFs hold Travere Therapeutics' stock?
Who are Travere Therapeutics' major shareholders?

Travere Therapeutics' stock is owned by many different retail and institutional investors. Top institutional investors include Armistice Capital LLC (9.83%), Vanguard Group Inc. (7.34%), Vanguard Group Inc. (7.25%), Kynam Capital Management LP (2.66%), Finepoint Capital LP (1.91%) and Parkman Healthcare Partners LLC (1.36%). Insiders that own company stock include Christopher R Cline, Elizabeth E Reed, Eric M Dube, Jula Inrig, Laura Clague, Noah L Rosenberg, Peter Heerma, Sandra Calvin, Steve Aselage and William E Rote.
View institutional ownership trends
.

How do I buy shares of Travere Therapeutics?

Shares of TVTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:TVTX) was last updated on 3/29/2024 by MarketBeat.com Staff

From Our Partners